Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 3

recruiting
3 973
countries
28
conditions
2 104

219 trials match your criteria

Study to Evaluate IOpener-Melanoma Test for Predicting Response to Immunotherapy in Stage III or IV Skin Melanoma Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Vusolimogene Oderparepvec with Nivolumab for Advanced Melanoma Patients Whose Cancer Progressed After Previous Immunotherapy Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dacarbazine Citrate

Study Comparing Nivolumab and Relatlimab with Chemotherapy to Pembrolizumab with Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Neoplasm

Recruiting

Study on Managing Rheumatological Side Effects in Cancer Patients Using Fludeoxyglucose (18F) and Checkpoint Inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ipilimumab

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atezolizumab

Study on Digital Monitoring of Symptoms in Patients with Advanced Kidney Cancer Treated with Cabozantinib and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib

Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Oral neoplasm

Recruiting

Study of Nivolumab for Patients with Oral Cancer to Reduce Tumor Size Before Surgery

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Study Comparing Ipilimumab and Nivolumab to Nivolumab Alone for Patients with Resectable Stage III Melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Study on IMA203 for Patients with Previously Treated Unresectable or Metastatic Skin Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on Nivolumab and MesoPher for Patients with Peritoneal Mesothelioma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.